Cynata Therapeutics Ltd has released a press release.
Product Development Program Update & Investor Presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
Cynata Therapeutics Limited on 6ix
In the deck
Story so far
Earlier from Cynata Therapeutics
- Positive 28-day Clinical Trial Data in Cohort B
- Research Collaboration with UNSW for Coronary Artery Disease
- Positive 6-Month Data from Cohort 1 in Phase 1 Trial in GvHD
- Cynatas MSCs Effective in Model of Diabetic Wounds
- $5.2m placement of shares to Fidelity International
Later from Cynata Therapeutics
- Cynata Enters Development Partnership with RCSI
- June 2018 Quarterly Report
- Cymerus MSCs improve cardiac recovery in preclinical study
- Appendix 4E & Financial Statements
- Cynata GvHD Trial Meets all Safety & Efficacy Endpoints
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics